Prevent complications · MICA
Assess fracture risk early and arrange follow-up.
Sources consulted 16 October 2026 · MICA scientific review to be confirmed
In adults receiving ≥2.5 mg/day prednisone equivalent for more than 3 months, assess fracture risk. Review fractures, falls and height loss; arrange bone density and vertebral fracture assessment when available. [1]
Optimise calcium/vitamin D intake and suitable activity. Moderate, high or very high risk warrants consideration of specific therapy under the guideline; calcium and vitamin D are not substitutes. Reassess risk and bone imaging, generally every 1–2 years during prolonged treatment. [1][2]
FRAX is not validated below age 40. Stopping denosumab requires planned sequential therapy to prevent bone loss and vertebral fractures. [2]
Personal reading prompts; no clinical data is recorded.
FICTIONAL LEARNING SCENARIO
Does a low daily dose exclude bone risk?
No: duration, previous fractures and other factors also matter. [2]
Non-exhaustive adult learning guidance. Check indication, contraindications, product information and local context before an individual decision. Cited recommendations do not establish marketing authorisation in Algeria.